Literature DB >> 23143595

Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing.

Julia Richter1, Matthias Schlesner, Steve Hoffmann, Markus Kreuz, Ellen Leich, Birgit Burkhardt, Maciej Rosolowski, Ole Ammerpohl, Rabea Wagener, Stephan H Bernhart, Dido Lenze, Monika Szczepanowski, Maren Paulsen, Simone Lipinski, Robert B Russell, Sabine Adam-Klages, Gordana Apic, Alexander Claviez, Dirk Hasenclever, Volker Hovestadt, Nadine Hornig, Jan O Korbel, Dieter Kube, David Langenberger, Chris Lawerenz, Jasmin Lisfeld, Katharina Meyer, Simone Picelli, Jordan Pischimarov, Bernhard Radlwimmer, Tobias Rausch, Marius Rohde, Markus Schilhabel, René Scholtysik, Rainer Spang, Heiko Trautmann, Thorsten Zenz, Arndt Borkhardt, Hans G Drexler, Peter Möller, Roderick A F MacLeod, Christiane Pott, Stefan Schreiber, Lorenz Trümper, Markus Loeffler, Peter F Stadler, Peter Lichter, Roland Eils, Ralf Küppers, Michael Hummel, Wolfram Klapper, Philip Rosenstiel, Andreas Rosenwald, Benedikt Brors, Reiner Siebert.   

Abstract

Burkitt lymphoma is a mature aggressive B-cell lymphoma derived from germinal center B cells. Its cytogenetic hallmark is the Burkitt translocation t(8;14)(q24;q32) and its variants, which juxtapose the MYC oncogene with one of the three immunoglobulin loci. Consequently, MYC is deregulated, resulting in massive perturbation of gene expression. Nevertheless, MYC deregulation alone seems not to be sufficient to drive Burkitt lymphomagenesis. By whole-genome, whole-exome and transcriptome sequencing of four prototypical Burkitt lymphomas with immunoglobulin gene (IG)-MYC translocation, we identified seven recurrently mutated genes. One of these genes, ID3, mapped to a region of focal homozygous loss in Burkitt lymphoma. In an extended cohort, 36 of 53 molecularly defined Burkitt lymphomas (68%) carried potentially damaging mutations of ID3. These were strongly enriched at somatic hypermutation motifs. Only 6 of 47 other B-cell lymphomas with the IG-MYC translocation (13%) carried ID3 mutations. These findings suggest that cooperation between ID3 inactivation and IG-MYC translocation is a hallmark of Burkitt lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23143595     DOI: 10.1038/ng.2469

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  52 in total

1.  Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up.

Authors:  Thorsten Zenz; Alexander Kröber; Katrin Scherer; Sonja Häbe; Andreas Bühler; Axel Benner; Tina Denzel; Dirk Winkler; Jennifer Edelmann; Carsten Schwänen; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Blood       Date:  2008-08-08       Impact factor: 22.113

Review 2.  c-myc hypermutation in Burkitt's lymphoma.

Authors:  J M Johnston; W L Carroll
Journal:  Leuk Lymphoma       Date:  1992-12

3.  PennCNV: an integrated hidden Markov model designed for high-resolution copy number variation detection in whole-genome SNP genotyping data.

Authors:  Kai Wang; Mingyao Li; Dexter Hadley; Rui Liu; Joseph Glessner; Struan F A Grant; Hakon Hakonarson; Maja Bucan
Journal:  Genome Res       Date:  2007-10-05       Impact factor: 9.043

4.  IMGT, the international ImMunoGeneTics database.

Authors:  M P Lefranc; V Giudicelli; C Ginestoux; J Bodmer; W Müller; R Bontrop; M Lemaitre; A Malik; V Barbié; D Chaume
Journal:  Nucleic Acids Res       Date:  1999-01-01       Impact factor: 16.971

5.  CREST maps somatic structural variation in cancer genomes with base-pair resolution.

Authors:  Jianmin Wang; Charles G Mullighan; John Easton; Stefan Roberts; Sue L Heatley; Jing Ma; Michael C Rusch; Ken Chen; Christopher C Harris; Li Ding; Linda Holmfeldt; Debbie Payne-Turner; Xian Fan; Lei Wei; David Zhao; John C Obenauer; Clayton Naeve; Elaine R Mardis; Richard K Wilson; James R Downing; Jinghui Zhang
Journal:  Nat Methods       Date:  2011-06-12       Impact factor: 28.547

6.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.

Authors:  Lili Wang; Michael S Lawrence; Youzhong Wan; Petar Stojanov; Carrie Sougnez; Kristen Stevenson; Lillian Werner; Andrey Sivachenko; David S DeLuca; Li Zhang; Wandi Zhang; Alexander R Vartanov; Stacey M Fernandes; Natalie R Goldstein; Eric G Folco; Kristian Cibulskis; Bethany Tesar; Quinlan L Sievers; Erica Shefler; Stacey Gabriel; Nir Hacohen; Robin Reed; Matthew Meyerson; Todd R Golub; Eric S Lander; Donna Neuberg; Jennifer R Brown; Gad Getz; Catherine J Wu
Journal:  N Engl J Med       Date:  2011-12-12       Impact factor: 91.245

7.  Burkitt lymphoma: much more than MYC.

Authors:  David Dominguez-Sola; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2012-08-14       Impact factor: 31.743

Review 8.  Translocations involving 8q24 in Burkitt lymphoma and other malignant lymphomas: a historical review of cytogenetics in the light of todays knowledge.

Authors:  E G Boerma; R Siebert; P M Kluin; M Baudis
Journal:  Leukemia       Date:  2008-10-16       Impact factor: 11.528

9.  Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.

Authors:  Roland Schmitz; Ryan M Young; Michele Ceribelli; Sameer Jhavar; Wenming Xiao; Meili Zhang; George Wright; Arthur L Shaffer; Daniel J Hodson; Eric Buras; Xuelu Liu; John Powell; Yandan Yang; Weihong Xu; Hong Zhao; Holger Kohlhammer; Andreas Rosenwald; Philip Kluin; Hans Konrad Müller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Martin D Ogwang; Steven J Reynolds; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Stefania Pittaluga; Wyndham Wilson; Thomas A Waldmann; Martin Rowe; Sam M Mbulaiteye; Alan B Rickinson; Louis M Staudt
Journal:  Nature       Date:  2012-08-12       Impact factor: 49.962

10.  Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data.

Authors:  Valentina Boeva; Tatiana Popova; Kevin Bleakley; Pierre Chiche; Julie Cappo; Gudrun Schleiermacher; Isabelle Janoueix-Lerosey; Olivier Delattre; Emmanuel Barillot
Journal:  Bioinformatics       Date:  2011-12-06       Impact factor: 6.937

View more
  182 in total

Review 1.  SCF ubiquitin ligase-targeted therapies.

Authors:  Jeffrey R Skaar; Julia K Pagan; Michele Pagano
Journal:  Nat Rev Drug Discov       Date:  2014-11-14       Impact factor: 84.694

2.  Mechismo: predicting the mechanistic impact of mutations and modifications on molecular interactions.

Authors:  Matthew J Betts; Qianhao Lu; YingYing Jiang; Armin Drusko; Oliver Wichmann; Mathias Utz; Ilse A Valtierra-Gutiérrez; Matthias Schlesner; Natalie Jaeger; David T Jones; Stefan Pfister; Peter Lichter; Roland Eils; Reiner Siebert; Peer Bork; Gordana Apic; Anne-Claude Gavin; Robert B Russell
Journal:  Nucleic Acids Res       Date:  2014-11-11       Impact factor: 16.971

3.  The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells.

Authors:  Jenny Zhang; Dereje Jima; Andrea B Moffitt; Qingquan Liu; Magdalena Czader; Eric D Hsi; Yuri Fedoriw; Cherie H Dunphy; Kristy L Richards; Javed I Gill; Zhen Sun; Cassandra Love; Paula Scotland; Eric Lock; Shawn Levy; David S Hsu; David Dunson; Sandeep S Dave
Journal:  Blood       Date:  2014-03-28       Impact factor: 22.113

4.  Alterations of microRNA and microRNA-regulated messenger RNA expression in germinal center B-cell lymphomas determined by integrative sequencing analysis.

Authors:  Kebria Hezaveh; Andreas Kloetgen; Stephan H Bernhart; Kunal Das Mahapatra; Dido Lenze; Julia Richter; Andrea Haake; Anke K Bergmann; Benedikt Brors; Birgit Burkhardt; Alexander Claviez; Hans G Drexler; Roland Eils; Siegfried Haas; Steve Hoffmann; Dennis Karsch; Wolfram Klapper; Kortine Kleinheinz; Jan Korbel; Helene Kretzmer; Markus Kreuz; Ralf Küppers; Chris Lawerenz; Ellen Leich; Markus Loeffler; Luisa Mantovani-Loeffler; Cristina López; Alice C McHardy; Peter Möller; Marius Rohde; Philip Rosenstiel; Andreas Rosenwald; Markus Schilhabel; Matthias Schlesner; Ingrid Scholz; Peter F Stadler; Stephan Stilgenbauer; Stéphanie Sungalee; Monika Szczepanowski; Lorenz Trümper; Marc A Weniger; Reiner Siebert; Arndt Borkhardt; Michael Hummel; Jessica I Hoell
Journal:  Haematologica       Date:  2016-07-06       Impact factor: 9.941

5.  A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma.

Authors:  Itziar Salaverria; Idoia Martin-Guerrero; Rabea Wagener; Markus Kreuz; Christian W Kohler; Julia Richter; Barbara Pienkowska-Grela; Patrick Adam; Birgit Burkhardt; Alexander Claviez; Christine Damm-Welk; Hans G Drexler; Michael Hummel; Elaine S Jaffe; Ralf Küppers; Christine Lefebvre; Jasmin Lisfeld; Markus Löffler; Roderick A F Macleod; Inga Nagel; Ilske Oschlies; Maciej Rosolowski; Robert B Russell; Grzegorz Rymkiewicz; Detlev Schindler; Matthias Schlesner; René Scholtysik; Carsten Schwaenen; Rainer Spang; Monika Szczepanowski; Lorenz Trümper; Inga Vater; Swen Wessendorf; Wolfram Klapper; Reiner Siebert
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

6.  Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.

Authors:  Ryan D Morin; Karen Mungall; Erin Pleasance; Andrew J Mungall; Rodrigo Goya; Ryan D Huff; David W Scott; Jiarui Ding; Andrew Roth; Readman Chiu; Richard D Corbett; Fong Chun Chan; Maria Mendez-Lago; Diane L Trinh; Madison Bolger-Munro; Greg Taylor; Alireza Hadj Khodabakhshi; Susana Ben-Neriah; Julia Pon; Barbara Meissner; Bruce Woolcock; Noushin Farnoud; Sanja Rogic; Emilia L Lim; Nathalie A Johnson; Sohrab Shah; Steven Jones; Christian Steidl; Robert Holt; Inanc Birol; Richard Moore; Joseph M Connors; Randy D Gascoyne; Marco A Marra
Journal:  Blood       Date:  2013-05-22       Impact factor: 22.113

7.  Inhibition of Hsp90 Suppresses PI3K/AKT/mTOR Signaling and Has Antitumor Activity in Burkitt Lymphoma.

Authors:  Lisa Giulino-Roth; Herman J van Besien; Tanner Dalton; Jennifer E Totonchy; Anna Rodina; Tony Taldone; Alexander Bolaender; Hediye Erdjument-Bromage; Jouliana Sadek; Amy Chadburn; Matthew J Barth; Filemon S Dela Cruz; Allison Rainey; Andrew L Kung; Gabriela Chiosis; Ethel Cesarman
Journal:  Mol Cancer Ther       Date:  2017-06-15       Impact factor: 6.261

8.  Identification of recurrent noncoding mutations in B-cell lymphoma using capture Hi-C.

Authors:  Alex J Cornish; Phuc H Hoang; Sara E Dobbins; Philip J Law; Daniel Chubb; Giulia Orlando; Richard S Houlston
Journal:  Blood Adv       Date:  2019-01-08

9.  A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma.

Authors:  Hae Yong Yoo; Min Kyung Sung; Seung Ho Lee; Sangok Kim; Haeseung Lee; Seongjin Park; Sang Cheol Kim; Byungwook Lee; Kyoohyoung Rho; Jong-Eun Lee; Kwang-Hwi Cho; Wankyu Kim; Hyunjung Ju; Jaesang Kim; Seok Jin Kim; Won Seog Kim; Sanghyuk Lee; Young Hyeh Ko
Journal:  Nat Genet       Date:  2014-03-02       Impact factor: 38.330

10.  The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition.

Authors:  Gabriele Varano; Simon Raffel; Martina Sormani; Federica Zanardi; Silvia Lonardi; Christin Zasada; Laura Perucho; Valentina Petrocelli; Andrea Haake; Albert K Lee; Mattia Bugatti; Ulrike Paul; Eelco Van Anken; Laura Pasqualucci; Raul Rabadan; Reiner Siebert; Stefan Kempa; Maurilio Ponzoni; Fabio Facchetti; Klaus Rajewsky; Stefano Casola
Journal:  Nature       Date:  2017-05-31       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.